Triple negative breast cancer (TNBC) becomes a major therapeutic challenge because of its poor overall outcome and lack of benefit from targeted therapy. NF-KB p65 has been implicated as a pivotal mediator of breast cancer cell growth and dysfunctions in apoptosis, and its expression correlates with a higher incidence of invasion and metastases. To validate the function of p65, p65miRNA was used to knock down p65 expression. Notably, reduced cell proliferation and increased apoptosis and suppressed invasiveness were observed in TNBC MDA-MB-231 cells. Study of the possible mechanism indicated that these effects occurred through silencing of the canonical NF-aleph B signaling pathway, as evidenced by decreased its transcriptional activity. These results provide evidence on the potential value of p65 inhibiting TNBC, which indicates great promise of p65 as a biomarker and a potential therapeutic target for TNBC.
语种：
外文
被引次数：
WOS：
中科院分区：
出版当年[2012]版：
大类|4 区生物
小类|4 区生化与分子生物学4 区生物工程与应用微生物4 区医学：研究与实验
最新[2025]版：
无
JCR分区：
出版当年[2012]版：
Q4BIOCHEMISTRY & MOLECULAR BIOLOGYQ4BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ4MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]Hebei Med Univ, Hebei Canc Inst, Hosp 4, Canc Res Ctr, Shijiazhuang, Hebei, Peoples R China[2]Bethune Int Peace Hosp, Dept Liver Dis, Shijiazhuang, Hebei, Peoples R China[3]Hebei Med Univ, Dept Hematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Wang Ling,Kang Fubiao,Shan Baoen,et al.Targeting NF-kappa B p65 with an artificial microRNA suppresses growth of MDA-MB-231 human triple-negative breast cancer cell line[J].GENE THERAPY AND MOLECULAR BIOLOGY.2012,14A:30-41.
APA：
Wang, Ling,Kang, Fubiao,Shan, Baoen,Liu, Lihong&Sang, Meixiang.(2012).Targeting NF-kappa B p65 with an artificial microRNA suppresses growth of MDA-MB-231 human triple-negative breast cancer cell line.GENE THERAPY AND MOLECULAR BIOLOGY,14A,
MLA：
Wang, Ling,et al."Targeting NF-kappa B p65 with an artificial microRNA suppresses growth of MDA-MB-231 human triple-negative breast cancer cell line".GENE THERAPY AND MOLECULAR BIOLOGY 14A.(2012):30-41
